These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8066864)

  • 1. [Risk factors of prostatic cancer].
    Friis S; Kjaer SK; Storm HH
    Ugeskr Laeger; 1994 Jun; 156(23):3485-90. PubMed ID: 8066864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cancer of the prostate. 1. Epidemiology].
    Mottet Auselo N; Costa P; Le Pellec L; Louis JF; Navratil H
    Prog Urol; 1995 Feb; 5(1):31-7. PubMed ID: 7536526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostate cancer--incidence and risk factors].
    Brasso K
    Ugeskr Laeger; 2007 May; 169(20):1883-6. PubMed ID: 17553361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
    Tanaka Y; Sasaki M; Shiina H; Tokizane T; Deguchi M; Hirata H; Hinoda Y; Okayama N; Suehiro Y; Urakami S; Kawakami T; Kaneuchi M; Pookot D; Igawa M; Okuyama A; Ishii N; Dahiya R
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):238-44. PubMed ID: 16492910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.
    Habuchi T; Suzuki T; Sasaki R; Wang L; Sato K; Satoh S; Akao T; Tsuchiya N; Shimoda N; Wada Y; Koizumi A; Chihara J; Ogawa O; Kato T
    Cancer Res; 2000 Jan; 60(2):305-8. PubMed ID: 10667581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human prostate cancer risk factors.
    Bostwick DG; Burke HB; Djakiew D; Euling S; Ho SM; Landolph J; Morrison H; Sonawane B; Shifflett T; Waters DJ; Timms B
    Cancer; 2004 Nov; 101(10 Suppl):2371-490. PubMed ID: 15495199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biology and treatment options during the development of prostate cancer].
    Lilleby W; Sudbø J; Fosså SD
    Tidsskr Nor Laegeforen; 2005 Mar; 125(5):571-4. PubMed ID: 15776028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiology of prostate cancer part II: the risk factors.
    Brawley OW; Knopf K; Thompson I
    Semin Urol Oncol; 1998 Nov; 16(4):193-201. PubMed ID: 9858325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate cancer screening (III): risk factors, natural history, course without treatment. Characteristics of detected cancers].
    Villers A; Soulié M; Haillot O; Boccon-Gibod L
    Prog Urol; 1997 Sep; 7(4):655-61. PubMed ID: 9410329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexual behaviour, history of sexually transmitted diseases, and the risk of prostate cancer: a case-control study in Cuba.
    Fernández L; Galán Y; Jiménez R; Gutiérrez A; Guerra M; Pereda C; Alonso C; Riboli E; Agudo A; González C
    Int J Epidemiol; 2005 Feb; 34(1):193-7. PubMed ID: 15375086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tea, coffee and prostate cancer.
    Lee AH; Fraser ML; Binns CW
    Mol Nutr Food Res; 2009 Feb; 53(2):256-65. PubMed ID: 18985656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hormone-related cancers: prostate cancer.
    Parnes HL; Thompson IM; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):368-77. PubMed ID: 15637399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas.
    Alipov G; Nakayama T; Ito M; Kawai K; Naito S; Nakashima M; Niino D; Sekine I
    Histopathology; 2005 Feb; 46(2):202-8. PubMed ID: 15693893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
    Platz EA; Giovannucci E
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etiological and epidemiological considerations in prostatic cancer.
    Bouffioux CR
    Scand J Urol Nephrol Suppl; 1980; 55():9-16. PubMed ID: 6938042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
    Carruba G
    J Cell Biochem; 2007 Nov; 102(4):899-911. PubMed ID: 17786930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of dietary factors in prostate cancer development].
    Zhu G; Zhang YQ; Wan B
    Zhonghua Nan Ke Xue; 2005 May; 11(5):375-8. PubMed ID: 15934465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.